Affect school and script analysis versus basic body awareness therapy in the treatment of psychological symptoms in patients with diabetes and high HbA1c concentrations: two study protocols for two randomized controlled trials by unknown
STUDY PROTOCOL Open Access
Affect school and script analysis versus
basic body awareness therapy in the
treatment of psychological symptoms in
patients with diabetes and high HbA1c
concentrations: two study protocols for two
randomized controlled trials
Eva O. Melin1,2,3*, Ralph Svensson4, Sven-Åke Gustavsson5, Agneta Winberg3, Ewa Denward-Olah3,
Mona Landin-Olsson1,6 and Hans O. Thulesius2,3,7
Abstract
Background: Depression is linked with alexithymia, anxiety, high HbA1c concentrations, disturbances of cortisol
secretion, increased prevalence of diabetes complications and all-cause mortality. The psycho-educational method
‘affect school with script analysis’ and the mind-body therapy ‘basic body awareness treatment’ will be trialled in
patients with diabetes, high HbA1c concentrations and psychological symptoms. The primary outcome measure is
change in symptoms of depression. Secondary outcome measures are changes in HbA1c concentrations, midnight
salivary cortisol concentration, symptoms of alexithymia, anxiety, self-image measures, use of antidepressants,
incidence of diabetes complications and mortality.
Methods: Two studies will be performed. Study I is an open-labeled parallel-group study with a two-arm
randomized controlled trial design. Patients are randomized to either affect school with script analysis or to basic
body awareness treatment. According to power calculations, 64 persons are required in each intervention arm at
the last follow-up session. Patients with type 1 or type 2 diabetes were recruited from one hospital diabetes
outpatient clinic in 2009. The trial will be completed in 2016. Study II is a multicentre open-labeled parallel-group
three-arm randomized controlled trial. Patients will be randomized to affect school with script analysis, to basic
body awareness treatment, or to treatment as usual. Power calculations show that 70 persons are required in each
arm at the last follow-up session. Patients with type 2 diabetes will be recruited from primary care. This study will
start in 2016 and finish in 2023. For both studies, the inclusion criteria are: HbA1c concentration ≥62.5 mmol/mol;
depression, alexithymia, anxiety or a negative self-image; age 18–59 years; and diabetes duration ≥1 year. The
exclusion criteria are pregnancy, severe comorbidities, cognitive deficiencies or inadequate Swedish. Depression,
anxiety, alexithymia and self-image are assessed using self-report instruments. HbA1c concentration, midnight
salivary cortisol concentration, blood pressure, serum lipid concentrations and anthropometrics are measured. Data
are collected from computerized medical records and the Swedish national diabetes and causes of death registers.
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Discussion: Whether the “affect school with script analysis” will reduce psychological symptoms, increase
emotional awareness and improve diabetes related factors will be tried, and compared to “basic body awareness
treatment” and treatment as usual.
Trial registration: ClinicalTrials.gov: NCT01714986
Keywords: Alexithymia, Anxiety, Cortisol, Depression, Diabetes mellitus, HbA1c, Mind-body therapy,
Randomized controlled trial, Psycho-education
Background
Diabetes is a progressive and demanding chronic disease,
which might cause secondary distress requiring emotional
adaptation [1]. An increased prevalence of depression is
found in patients with diabetes [2, 3]. The comorbidity is
linked with inadequate glycemic control [4], disturbances
in cortisol secretion [3, 5], increased prevalence of dia-
betes complications [6, 7] and all-cause mortality [7].
Affects are the innate, unconscious and strictly bio-
logical portions of emotions [8–12]. Deficits in the aware-
ness of affects result in abnormal physiological reactions
and impaired capacity for self-care and self-regulation
[13]. Alexithymia includes difficulties in identifying and
describing feelings, as well as low capacity for introspec-
tion and reflection [13, 14]. Alexithymia has been demon-
strated as a risk factor of depression but the number and
prevalence of alexithymic features might also increase
during depressive episodes [15]. Type 1 diabetes [16],
inadequate glycemic control of diabetes [17], reflexive
emotional eating and obesity [18–20] and increased car-
diovascular mortality [21] have been linked to alexithymia.
Anxiety has been associated with depression [4] and inad-
equate glycemic control [22].
A negative self-image, which includes self-hate, self-
ignorance or self-blame, is often present in persons with
eating disorders [23], which, in turn, are associated with
inadequate glycemic control [24].
High concentrations of HbA1c [25, 26] and disturbances
in cortisol secretion [27, 28] are linked to complications of
diabetes.
The psycho-educational method ‘affect school with script
analysis’ (ASSA) was constructed by Bergdahl and Armelius
[29, 30], inspired by Silvan S. Tomkins’ affect theory [8–11]
and its interpretation by Nathanson [12] and Monsen and
Monsen [31]. This method has previously been shown to
decrease alexithymia [32] and stress symptoms [30].
‘Basic body awareness therapy’ (BBAT) is a physiother-
apeutic mind-body therapy [33], where increased body
awareness and increased integration between body and
mind are key elements, as in other mind-body therapies
such as Tai Chi, yoga, meditation and mindfulness-based
therapies. In Sweden, BBAT is used in both psychiatric
and primary care settings for treating psychiatric and
somatic health issues [34–36].
Objective and research questions
Studies I and II
The main hypothesis in these two studies is that an
increased emotional awareness and verbal expressiveness
might have beneficial health implications, such as lessening
of depressive symptoms. The primary outcome measure is
change in symptoms of depression. Secondary outcome
measures are changes in symptoms of alexithymia, anxiety,
self-image measures, HbA1 concentrations, midnight
salivary cortisol concentration, use of antidepressants and
incidence of diabetes complications and mortality.
Study I
The main aim is to compare the effects of ASSA and
BBAT in patients with type 1 or type 2 diabetes, psycho-
logical symptoms and inadequate glycemic control.
Study II
The main aim is to compare ASSA, BBAT with only treat-
ment as usual in patients with type 2 diabetes, psycho-
logical symptoms and inadequate glycemic control.
Methods/design
Study design
These studies were registered with ClinicalTrials.gov on
24 October 2012 (NCT01714986). The final report will
follow the CONSORT extension for non-pharmaceutical
interventions.
Intervention with ASSA and BBAT will be tried in two
studies with different study designs for patients with
type 1 or type 2 diabetes, psychological symptoms and
inadequate glycemic control in Region Kronoberg,
Sweden. Results from the two studies will be presented
separately but will also be compared.
Study I
This is an open-labeled parallel-group study with a
two-arm randomized controlled trial design, which
was initiated in 2009 and will be complicated in 2016
for patients with type 1 or type 2 diabetes recruited from
one hospital diabetes outpatient clinic.
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Study II
This is a multicentre open-labeled parallel-group study with
a three-arm randomized controlled trial design, which will
start in 2016 and will be completed in 2023 for patients
with type 2 diabetes recruited from primary care units.
Participants and procedure
Inclusion criteria for baseline analysis (Fig. 1)
These are outlined in Fig. 1. For Study I, participants must
have either type 1 or type 2 diabetes. For Study II, partici-
pants must have type 2 diabetes. For both studies, partici-
pants must be aged 18–59 years, have had diabetes for at
least 1 year and must provide signed informed consent.
Exclusion criteria
These are outlined in Fig. 1. For both studies, exclusion
criteria are:
 Pregnancy
 Severe comorbidities, if it is anticipated that
participation would be difficult or unsafe for the
patient (end-stage renal disease, cancer, hepatic failure,
visual impairment to such a degree that reading
questionnaires would be impossible, impaired hearing
to such a degree that participation in discussions
during the group sessions would not be possible,
psychotic disorders, bipolar disorder, suicide ideation,
severe personality disorder, or severe substance abuse)
 Cognitive deficiencies (mental retardation, stroke or
dementia)
 Inadequate knowledge of Swedish.
Intervention criteria
For both studies, these are either a HbA1c concentration
of at least 62.5 mmol/mol or at least one of: self-
reported depression, anxiety, alexithymia or a negative
self-image (Fig. 1).
Recruitment
In both studies, patients will be recruited at regular bi-
annual visits for diabetes control. Nurses specializing in
diabetes will send detailed information about the study
together with calls for diabetes controls to patients with-
out known criteria for exclusion. At the diabetes control
visit, the information will be repeated, and re-evaluation
for prevalent exclusion criteria will be performed. The
recruitment period will last for 9 months at each unit.
Baseline data and measurements (T0) will be collected
after signed informed consent has been obtained. The
patients are informed that they can withdraw from the
study at any time without negative consequences.
Randomization and allocation
The randomization and allocation of the coded patients
will be performed by an independent statistician with
Fig. 1 Description of criteria for randomization and allocation to ASSA (Studies I and II), BBAT (Studies I and II) and treatment as usual (Study II)
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the purpose of having as equal distribution as possible of
sex and age in each intervention arm.
Study I This is outlined in Fig. 2. Patients who fulfilled
the criteria were randomized into two intervention arms,
ASSA (group 1) or BBAT (group 2). After allocation, the
ASSA and BBAT instructors offered renewed oral infor-
mation and patients made their final decisions regarding
participation. Group 3 consists of patients who fulfilled
the criteria but refused participation after allocation, and
group 4 consists of patients who did not fulfil the cri-
teria. Groups 3 and 4 will be followed as comparison
groups.
Study II This is outlined in Fig. 3. Patients fulfilling the
intervention criteria will be randomized into three arms:
ASSA (group 1), BBAT (group 2) or no intervention
(treatment as usual; group 3). Group 4 will consist of pa-
tients who fulfil the criteria but refuse participation after
allocation. Group 5 will consist of patients who do not
fulfil the criteria.
Schedule for assessments
Study I This is shown in Fig. 2. Assessments were per-
formed for participants in ASSA and BBAT at baseline
(T0), prior to intervention (T1) and after termination of
the intervention (T2) and will be performed 7 years after
T0 (T4). For nonparticipants (Groups 3 and 4), assess-
ments were performed at T0 and will be repeated at T4.
Study II Assessments will be performed for Groups 1, 2
and 3 at T0, T1 and T2; 1 year after T2 (T3) and at T4.
For Groups 4 and 5, assessments will be performed at
T0 and T4.
Assessments, measurements and data collection at T0 and T4
Studies I and II Assessments will be performed using
self-report instruments; HbA1c concentration, midnight
salivary cortisol concentration, blood lipids, blood pressure,
and anthropometrics will be measured (Figs. 2 and 3). Data
will be retrieved from computerized medical records and
from the Swedish national diabetes register. At T4, mortal-
ity data will be collected from the Swedish causes of death
register.
Assessments and measurements at T1, T2 and T3
For Study I, assessments will be made using self-report
instruments and HbA1c concentrations will be measured
at T1 and T2 (Fig. 2).
For Study II, assessments will be performed with self-
report instruments and HbA1c will be measured at T1,
T2 and T3 (Fig. 3).
Additional data collection concerning medication
between measuring points
Data will be collected regarding changes in medication that
occur between measuring points. The use of antidepres-
sants will be monitored. There will be three categories: (1)
no antidepressants; (2) use of a single antidepressant drug;
(3) combinations of antidepressant drugs. Amounts of
Fig. 2 Study flow chart for Study I
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stops and starts will be registered as well as the total time
for each category. Type of antidepressants according to of-
ficial classification will be registered. The use of insulin will
be categorized as: (1) no insulin; (2) single or multiple daily
injections; (3) continuous subcutaneous insulin infu-
sion. The duration of the period of each category will
be monitored. All non-insulin antidiabetic drugs will
be registered according to their official classification
and the time that participants have used each drug will be
monitored.
Intention to treat analysis
Studies I and II
Differences at T0 between participants and nonpartici-
pants fulfilling criteria will be analyzed regarding age,
sex, self-reported depression and anxiety, alexithymia,
self-image, clinical psychiatric diagnoses, smoking, phys-
ical inactivity, metabolic variables, medication and sick-
leave status and will be thoroughly described. Levels of
HbA1c will be determined for all patients who par-
ticipate in the interventions, but decline to complete
the questionnaires at T2, T3 (Study II only) or T4. At
T4, all patients who participated at T0 will be asked
for oral and written consent to participate in all the
assessments, measurements and data collection that
are included at T4. If full assessments are not pos-
sible we will collect data regarding HbA1c concentra-
tions, mortality, diabetes complications and use of
antidepressants.
Written and oral informed consent
Written and oral informed consent will be received from
each participant in both studies at T0 and at T4, and oral
consent after allocation to intervention (Figs. 2 and 3).
The studies were approved by the Regional Ethical
Review Board of Linköping University, Linköping (regis-
tration no. M120-07, T83-08).
Self-report instruments
Studies I and II
The Hospital Anxiety and Depression Scale will be used
at all measuring points to assess self-reported anxiety
and depression [4, 5, 32, 37–39]. The cut-off level for
each subscale recommended by the constructors of this
scale (≥8 points) will be used for inclusion in the inter-
vention [38]. In a study that compared the Swedish ver-
sion of the Hospital Anxiety and Depression Scale with
a structured clinical interview for DSM-III criteria, the
optimal cut-off level for screening was ≥5 points for
both subscales [39].
The 20-item Toronto Alexithymia Scale will be used
at all measuring points to assess alexithymia [4, 19, 32,
37, 40–42]. This scale consists of 20 statements rated
from 1 to 5, and is based on three subscales: ‘difficulty
identifying feelings’ (seven statements), ‘difficulty describ-
ing feelings’ (five statements) and ‘externally oriented feel-
ings’ (eight statements).The recommended cut-off level
(≥61 points) will be used for inclusion in the inter-
vention [41, 42].
Fig. 3 Study flow chart for Study II
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The affinity dimension of the Structural Analysis of
Social Behavior assessment tool will be used to assess
self-image [23, 35, 43]. This test consists of 36 state-
ments with response options on a scale between 0 and
100; the results are summarized into eight clusters. High
scores for the clusters ‘blaming self ’, ‘hating self ’ and
‘ignoring self ’; and low scores for the clusters ‘accepting
self ’, ‘loving self ’ and ‘nourishing self ’ form a negative
self-image. A negative self-image is defined as results
below 284 points. The Structural Analysis of Social Behav-
ior test will be used at T0 and at T4.
Measurements
Study I and II
According to the Swedish national guidelines for dia-
betes management in 2009, the recommended goal for
treatment was for HbA1c concentrations of less than 52
mmol/mol. However, since goals should be individual-
ized, a higher cut-off value was chosen in this study:
venous HbA1c concentration (IFCC units) ≥62.5 mmol/
mol, (Mono-S ≥7 %, NGSP ≥7.87 %) [44]. Analyses will
be performed with high pressure liquid chromatography,
(HPLC - variant II, Turbo analyzer, Bio-Rad®, Hercules,
CA, USA) [45].
Serum lipids will be analyzed using the enzymatic
colour test (Olympus AU®, Tokyo, Japan). Blood lipids
and HbA1c will be analyzed at the Department of Clinical
Chemistry, Växjö Central Hospital.
Blood pressure, waist circumference, weight and length
will be measured by a nurse, according to standard
procedures. Abdominal obesity is defined for men as waist
circumference ≥1.02 m. and for women as waist circum-
ference ≥0.88 m [4, 5]. General obesity is defined as body
mass index ≥30 kg/m2 for both sexes [4].
Midnight salivary samples will be collected between
23.30 and 00.30 hours using a Salivette sampling device
[5, 46–49] (Salivette®, Sarstedt, Nümbrecht, Germany).
Assays will be performed at the Department of Clinical
Chemistry, Lund University Hospital, Lund, using Roche
Cobas Cortisolassay®, a competitive electrochemilumines-
cence immunoassay [5, 46–49], using an Elecsys 2010
immunoanalyzer system (Roche Diagnostics, Mannheim,
Germany). Patients will receive written and oral instruc-
tions before sampling [5].
Data collection
For both studies, data regarding patients’ diagnoses, dia-
betes complications, life style factors, medication, psycho-
therapy, diabetes-related medication and antidepressants
and sick leave will be collected from the Swedish national
diabetes register, from medical records from the depart-
ments of internal medicine, ophthalmology and psych-
iatry, and from primary care centres. Data from all
hospital clinics, the psychiatry department and all primary
care centres (including psychotherapy obtained in primary
care) are available as they are connected to the same
computer system (Cambio Cosmic ®). Mortality data will
be collected from the Swedish causes of death register.
Definitions of diabetes complications and severe
hypoglycemia episodes
Foot complications are defined as neuropathy, angiopathy,
previous or current diabetes foot ulcer, foot infection, foot
deformity, arthropathy, or amputation of the lower limb
[4]. Diabetes retinopathy is defined as nonproliferative or
proliferative retinopathy with microangiopathy changes,
as viewed by fundus photography through a dilated pupil
[4]. Macrovascular complications are defined as ischemic
heart disease (angina pectoris, previous myocardial infarc-
tion, percutaneous transluminal coronary angioplasty or
coronary artery bypass graft surgery); stroke or transient
ischemic attack [4]. End-stage renal disease is defined as a
state where dialysis or a renal transplant is necessary [50].
A severe hypoglycemic episode is defined as one in which
help is needed from another person owing to hypo-
glycemia; episodes occurring during the previous 6 months
will be registered [4, 5].
Definitions of smoking and physical inactivity
Patients are defined as smokers if they have smoked any
amount of tobacco during the last year [4, 5]. In the
Swedish national diabetes register, physical activity is
categorized into four groups: moderate activities for ≥30
minutes, less than once a week, once a twice a week,
3–5 times/week, or daily. Patients are defined as physic-
ally inactive if they perform moderate activities, such as
30 minutes of walking, less than once a week [4, 5].
Affect school and script analysis – a psycho-educational
method
Studies I and II
The intervention comprises eight weekly sessions of a
group with five to seven participants (‘affect school’)
with two instructors followed by ten weekly individual
sessions (‘script analysis’). Two psychotherapists and one
physician are recruited as instructors for both studies.
They were trained together to become instructors by the
constructors of the ASSA method, and have been in-
structors together in several ASSA groups. The same
two instructors participate in all eight group sessions,
which render three possible combinations: physician and
psychotherapist I; physician and psychotherapist II; and
psychotherapist I and psychotherapist II. The patients
could be considered clustered within the pair of instruc-
tors. Patients will also be clustered by the set of five to
seven participants included in each group. As depression
is the main outcome measure we will test associations
between depression symptoms, instructors and groups.
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Only one room will be used for all group sessions in
each study.
At each affect school session a specific information
handout is distributed, containing affect and script the-
ory and the topics for the affect discussion. The scheme
for the affect school sessions is presented in Table 1.
During the first part of each affect school session the
participants are instructed on general affect theory, and
specific theory regarding the particular innate affects
that are the topics for the session, followed by script the-
ory. During the second part, the affect discussion, partici-
pants are encouraged to tell single-event autobiographical
memory narratives; this exercise is considered important
in psychotherapy [51]. The goal of the affect school is to
achieve increased emotional awareness and verbal expres-
siveness. The affect theory presented during the affect
school group sessions is essential for the script analysis,
and we consider that participation in at least five group
sessions is necessary to obtain an understanding of the
theory. Persons with lower participation rate will not be
offered script analysis. The total participation rate in
ASSA will be counted.
During the individual sessions (script analysis), the
patient is encouraged to focus on one or two affects that
he or she finds particularly difficult to handle, and the
patient’s scripts for handling these affects are discussed.
These sessions are performed by psychotherapists or
social counsellors.
Here follows a short description of the affect theory
that will be presented during the group sessions. A more
complete description is presented elsewhere [37]. Essential
in the affect school are the five concepts of affects, feel-
ings, emotions, mood and scripts. Affects are the innate,
unconscious and strictly biological portions of emotions.
Each affect has a specific programme involving face
mimicry, body gestures, voice and autonomous nervous
and hormone system physiology. The innate affects are
enjoyment-joy, interest-excitement, surprise-startle, fear-
terror, anger-rage, distress-anguish, shame-humiliation,
distaste and dissmell. Pain has features of both an affect
and a drive. Affects are important messengers to the self.
The primary functions of the innate affects are to regulate
drives, such as hunger and sexuality. The secondary func-
tions are to regulate other affects. Feelings are the con-
scious portions of emotions. Emotions reflect biography. A
triggered affect evokes memories of earlier situations and
relationships where this affect has been triggered before
and, in addition, other affects triggered in the earlier situa-
tions will be triggered again in the present situation. An
emotion lasts as long as memory continues to trigger the
involved affects. Mood is defined as a persistent state of
emotion. Anxiety and depression are subsequently mood
disorders. Scripts are learned patterns to handle emotions.
Basic body awareness therapy – a physiotherapeutic
mind-body therapy
Studies I and II
This comprises ten weekly sessions for a group of five to
seven participants with one instructor responsible for all
sessions. Three physiotherapists, with special BBAT edu-
cation and clinical experience of being BBAT instructors
are recruited for both group and individual sessions in
both studies. Before intervention, the BBAT instructors
meet and synchronize how they will perform the inter-
ventions. The patients are clustered by BBAT instruc-
tors. Patients will also be clustered by the set of five to
seven participants included in each group. We will test
associations between depression symptoms, instructors
and group. Only one room will be used for all group ses-
sions in each study. Breathing, grounding, stability in the
central line, centring, flexibility and flow are features sys-
tematically trained at each session. Patients are encouraged
Table 1 General programme for the eight affect school sessions
Affect theory
General affect theory is presented at all sessions. Specific affect theory




3) Interest and surprise
4) Shame
5) Anger
6) Distaste and dissmell
7) Distress
8) Pain
Script theory presented at each session
1) Affects and experiences together form the individual scripts.
2) How we act in different situations and how we interpret
experiences depending on our scripts.
3) Scripts are formed by family rules and common cultural rules
for how affects should be handled.
4) Intensity and expressions of emotion are controlled by scripts.
5) Affects can be completely suppressed and thereby unconscious.
Break for coffee or tea
Affect discussion
Main topics for the affect discussions follow the programme for the
eight sessions. Questions used in the affect discussions are:
1) Tell of a situation when you felt…
2) How do you know that you feel…?
3) Do you feel it in a particular place in the body?
4) Does it happen often?
5) How do you know that someone else is…?
6) Can you understand and accept another person’s…?
7) How does… influence your personal relationships?
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to observe and accept the sensations and emotions that
awaken during the treatment situations. Patients systemat-
ically train to discern and differentiate between thoughts,
emotions and body sensations. Continuous training and
repetition are fundamental parts of BBAT [36].
Patients are offered five individual sessions where they
focus on their own particular difficulties.
To balance the two intervention methods patients par-
ticipating in fewer than five group sessions will not be
offered any individual sessions. The total participation
rate will be counted.
Enhanced body awareness and a greater unity between
body and self are important goals [33]. Body awareness
is the subjective, phenomenological aspect of propriocep-
tion and interoception that enters conscious awareness,
and is modifiable by mental processes including attention,
interpretation, appraisal, beliefs, memories, conditioning,
attitudes and affects [33]. Important in BBAT is breathing,
which is regarded as a central connector between body and
mind. Improved body and mind integration is achieved by
noticing, discerning, and differentiating thoughts, emotions
and body sensations [33].
Measures to enhance participation
In both studies, participants are offered ‘preventive sick
leave’ for the time spent in group or individual sessions
by the Swedish Social Insurance Agency, as a measure to
enhance participation.
Discontinuation of intervention with ASSA and BBAT
In both studies, if anything should happen to patients
during the intervention so that they fulfil the exclusion
criteria, they will be advised to withdraw. In case of psy-
chiatric complications as a result of the interventions,
patients will be offered personal counselling or referral
to a psychiatric unit.
Treatment as usual
In both studies, there will be no restriction on the use of
treatment as usual, such as psychotherapeutic or phy-
siotherapeutic treatment, antidepressant medication or
diabetes-related treatment.
Primary and secondary outcome measures
In both studies, the primary outcome measure is the
change in depression symptoms. Secondary outcome mea-
sures are changes in alexithymia and anxiety symptoms
and self-image measures; changes in HbA1c concentration
and midnight salivary cortisol concentration; use of anti-
depressants, and incidence of diabetes complications and
mortality.
Power calculations for sample size
The standard deviation was 2.8 for the individual changes
of Hospital Anxiety and Depression Scale – depression
subscale after our intervention with ASSA for patients
with chronic benign pain (calculated from raw data) [32].
Study I
If we assume that the standard deviation for the individ-
ual changes in Hospital Anxiety and Depression Scale –
depression subscale in this study is 2.8, a change of 1.4
points represents half the standard deviation, which is
considered indicative of clinically relevant changes in
subjective symptoms [52]. Calculating a statistical power
of 80 %, and assuming significance at the 0.05 level, 64
persons in each intervention arm are required at follow-
up in a two-arm randomized controlled trial. Unfortu-
nately we only recruited around 21 persons in each arm in
Study I, rendering a power of 37 %.
Study II
The power calculation is based on an analysis of vari-
ance (ANOVA), where two groups have the same means
and one differs with 1.4 points, using the same standard
deviation (2.8) as in Study I. Calculating a statistical
power of 80 %, calculated using an ANOVA, 60 persons
are required. However, using the Kruskal–Wallis test
reveals that it is necessary to increase this by 15 %; thus,
70 persons are required in each arm in a three-arm ran-
domized controlled trial.
Studies I and II
In the previously mentioned intervention with ASSA,
approximately 10 % of participants did not answer the
self-report instruments after the intervention [32]. If we
assume the same answering rate, 10 % more patients
have to be included in each arm.
Statistical analysis
Study I
The Wilcoxon signed rank test and the Kruskal–Wallis
test will be used for changes in non-normally distributed
variables (for psychological symptoms measured using
the self-report instruments and for midnight salivary
cortisol concentration).
Study II
The Kruskal–Wallis test will be used for changes in non-
normally distributed variables (psychological symptoms
and midnight salivary cortisol concentration).
Studies I and II
A paired-samples t test will be used for continuous and
normally distributed variables (HbA1c concentration).
The associations between outcome variables and baseline
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characteristics will be modelled using linear regression
analysis (HbA1c concentration, midnight salivary cor-
tisol concentration, psychological symptoms); logistic
regression analysis will be used for categorical out-
comes (incidence of diabetes complications and use of
antidepressants).
Cox proportional-hazards regression will be used to
analyze effects on mortality. Missing values of the self-
report instruments will be imputed using multinomial
logistic regression on the other variables in the same
subgroup [53]. Imputation will be performed for the de-
pression and anxiety subscales of the Hospital Anxiety
and Depression Scale if there are at most two missing
items for each subscale; for the 20-item Toronto Alex-
ithymia Scale if there is at most one missing item for
each subscale (‘difficulty identifying feelings’, ‘difficulty
describing feelings’ and ‘externally oriented feelings’) and
for the Structural Analysis of Social Behavior tool if
there is at most one missing item for each of the eight
clusters. Statistical significance will be considered for
P < 0.05.
Discussion
Diabetes is a progressive and demanding chronic disease,
which requires emotional adaptation [1]. Previous re-
search has shown that alexithymia is a risk factor for
depression [15], which is deleterious for patients with
diabetes [4–7]. Also, a deficit in the awareness of affects
results in abnormal physiological reactions and impaired
capacity for self-care [13]. An advanced capacity for self-
care is necessary in diabetes.
For this reason, we were interested in finding interven-
tions focusing on increased emotional awareness and
verbal expressiveness. We have chosen to test the ASSA
[30, 32, 37] against BBAT [34–36] in two studies. In
Study I, we perform a two-arm randomized controlled
trial with patients with type 1 or type 2 diabetes from
one hospital diabetes outpatient clinic. In Study II,
ASSA, BBAT and ‘treatment as usual’ will be compared
in a three-arm randomized controlled trial for patients
with type 2 diabetes from primary care units.
We expect the ASSA method to be more efficient than
BBAT in reducing depressive symptoms. In the ASSA
intervention, patients are systematically trained to iden-
tify and describe feelings, and are also presented with
advanced affect theory. In BBAT, patients focus more on
bodily features, such as breathing, grounding, stability,
centring, flexibility and flow [36]. The patients undergo-
ing BBAT are not systematically trained to identify and
describe feelings but they are encouraged to observe and
accept sensations and emotions that awaken during the
treatment sessions [36]. As neither of the two interven-
tions is ‘placebo’, we think it is important to compare
both ASSA and BBAT with treatment as usual.
We have chosen reduction of depression symptoms as
the primary outcome measure, even though some pa-
tients were not depressed at the time of inclusion. A re-
duction in depression symptoms might be of value even
for patients not fulfilling our criteria for self-reported
depression. A lower cut-off level (≥5 points) has been
proposed for the depression subscale of the Swedish ver-
sion of Hospital Anxiety and Depression Scale than we
have chosen to use. This means that the sensitivity for
depression might be less than optimal in our study [39].
One limitation to our studies is that we only use self-
report instruments, not structured interviews. Another
limitation is that not enough patients in the first part of
our randomized controlled trial agreed to participate in
the intervention, so randomizing into three arms (ASSA,
BBAT and a no-intervention group) was impossible. We
aim to recruit more patients in Study II, to be able to
perform the three-arm randomized controlled trial.
We foresee recruitment difficulties. Patients have gen-
erally not previously been introduced to the idea that
emotional factors might impact their disease; presum-
ably neither ASSA nor BBAT are methods known to the
patients. Patients may feel that it is stressful to talk
about emotions in a group situation and therefore BBAT
may be more easily accepted.
Another difficulty is that most patients are working or
university students, which might make participation dif-
ficult, therefore the Swedish Social Insurance Agency
will offer preventive sick-leave compensation for treat-
ment session time. It is, however, not possible to offer
preventive sick-leave compensation for nonparticipants.
The clustering within the pair of instructors in ASSA
might affect the results, but this will be tested. The three
ASSA instructors were trained together, and have previ-
ously been ASSA instructors together in all three possible
combinations; this will probably minimize the effects of
clustering. The three BBAT instructors all have special
training and long experience, but have not been trained
together; however, they will co-operate in synchronizing
how they will perform the BBAT intervention. The results
of the interventions might be influenced by the group
members being randomized into each group and by study
design. Previously, we have carefully selected patients who
we thought could benefit from the ASSA intervention and
would not disturb the group dynamics. In the current
studies, no individual selection can be made by the in-
structors, owing to the study design. Previously, we have
made contracts with the patients to do their very best to
participate in all sessions. In the current studies, we have
declared that they can stop participating at any time.
In summary, depression is a serious disease in patients
with diabetes. Intervention with ASSA and BBAT will be
tried for patients with diabetes, psychological symptoms
and inadequate glycemic control, first in one two-arm
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randomized controlled trial and then in one three-arm
randomized controlled trial.
Trial status
Patients from the hospital outpatient clinic were recruited
in 2009 with the final follow-up section expected to take
place in 2016. Recruitment from primary care centres will
start in 2016.
Abbreviations
ASSA: affect school and script analysis; BBAT: basic body awareness therapy;
CONSORT: Consolidated Standards of Reporting Trials; IFCC: International
Federation of Clinical Chemistry; NGSP: National Glycohemoglobin
Standardization Program.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EOM initiated and received funding for this study. EOM, RS, S-ÅG, AW, ED-O,
ML-O and HOT contributed to the study design and to implementation; they
participated as investigators and reviewed and edited the manuscript. EOM,
RS and S-ÅG participated as ASSA instructors. AW and ED-O participated as
BBAT instructors. EOM wrote the statistical methods and manuscript, is the
guarantor of this work and, as such, will have full access to all the data in
the study and will take responsibility for the integrity of the data and the
accuracy of the data analysis. All authors read and approved the manuscript.
Acknowledgement
The authors are indebted to Anna Lindgren, PhD, at the Department of
Mathematical Statistics, Lund University, Lund, Sweden for the power
calculations.
Funding
The study is supported by grants from the Unit for Research and
Development, Region Kronoberg, Växjö, Sweden and from the South
Swedish Region Council, Lund, Sweden.
Author details
1Department of Clinical Sciences, Endocrinology and Diabetes, Lund
University, Lund, Sweden. 2Department of Research and Development,
Region Kronoberg, Box 1223, SE-351 12 Växjö, Sweden. 3Primary Care, Region
Kronoberg, Växjö, Sweden. 4Department of Psychology, Linnaeus University,
Växjö, Sweden. 5Department of Psychiatry, Region Kronoberg, Växjö, Sweden.
6Department of Endocrinology, Lund University Hospital, Lund, Sweden.
7Department of Clinical Sciences, Family Medicine, Lund University, Malmoe,
Sweden.
Received: 18 September 2014 Accepted: 18 April 2016
References
1. Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and
distress in patients with diabetes: a call for greater clarity and precision.
Diabet Med. 2014;31:764–72.
2. Semenkovich K, Brown ME, Svrakic DM, Lustman PJ. Depression in type 2
diabetes mellitus: prevalence, impact, and treatment. Drugs. 2015;75:577–87.
3. Korczak DJ, Pereira S, Koulajian K, Matejcek A, Giacca A. Type 1 diabetes
mellitus and major depressive disorder: evidence for a biological link.
Diabetologia. 2011;54:2483–93.
4. Melin EO, Thunander M, Svensson R, Landin-Olsson M, Thulesius HO.
Depression, obesity and smoking were independently associated
with inadequate glycemic control in patients with type 1 diabetes.
Eur J Endocrinol. 2013;168:861–69.
5. Melin EO, Thunander M, Landin-Olsson M, Hillman M, Thulesius HO.
Depression, smoking, physical inactivity and season independently
associated with midnight salivary cortisol in type 1 diabetes.
BMC Endocr Disord. 2014;14:75.
6. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association
of depression and diabetes complications: a meta-analysis. Psychosom Med.
2001;63:619–30.
7. Egede LE, Nietert PJ, Zheng D. Depression and all-cause and coronary heart
disease mortality among adults with and without diabetes. Diabetes Care.
2005;28:1339–45.
8. Tomkins SS. Affect, imagery, consciousness: the positive affects, vol. 1.
New York: Springer; 1962.
9. Tomkins SS. Affect, imagery, consciousness. the negative affects, vol. 2.
New York: Springer; 1963.
10. Tomkins SS. Affect, imagery, consciousness: the negative affects: anger and
fear. New York: Springer; 1991.
11. Tomkins SS. Affect, imagery, consciousness. Cognition: duplication and
transformation of information, vol. 4. New York: Springer; 1992.
12. Nathanson DL. Shame and pride, affect, sex, and the birth of the self.
London: Norton; 1992.
13. Nemiah J, Sifnoes P. Affect and fantasy in patients with psychosomatic
disorder. In: Ow H, editor. Modern trends in psychosomatic medicine, vol. 2.
London: Butterworths; 1970. p. 26–34.
14. Taylor GJ, Bagby RM. Psychoanalysis and empirical research: the example of
alexithymia. J Am Psychoanal Assoc. 2013;61:99–133.
15. Tolmunen T, Heliste M, Lehto SM, Hintikka J, Honkalampi K, Kauhanen J.
Stability of alexithymia in the general population: an 11-year follow-up.
Compr Psychiatry. 2011;52:536–41.
16. Chatzi L, Bitsios P, Solidaki E, Christou I, Kyrlaki E, Sfakianaki M, et al. Type 1
diabetes is associated with alexithymia in nondepressed, non-mentally ill
diabetic patients: a case-control study. J Psychosom Res. 2009;67:307–13.
17. Housiaux M, Luminet O, Van Broeck N, Dorchy H. Alexithymia is associated
with glycaemic control of children with type 1 diabetes. Diabetes Metab.
2010;36:455–62.
18. Zijlstra H, van Middendorp H, Devaere L, Larsen JK, van Ramshorst B,
Geenen R. Emotion processing and regulation in women with morbid
obesity who apply for bariatric surgery. Psychology & Health. 2012;27:1375–87.
19. Elfhag K, Lundh LG. TAS-20 alexithymia in obesity, and its links to
personality. Scand J Psychol. 2007;48:391–98.
20. Chesler BE. Emotional eating: a virtually untreated risk factor for outcome
following bariatric surgery. ScientificWorld J. 2012. doi:10.1100/2012/365961.
21. Tolmunen T, Lehto SM, Heliste M, Kurl S, Kauhanen J. Alexithymia is
associated with increased cardiovascular mortality in middle-aged Finnish
men. Psychosom Med. 2010;72:187–91.
22. Anderson RJ, Grigsby AB, Freedland KE, de Groot M, McGill JB, Clouse RE, et
al. Anxiety and poor glycemic control: a meta-analytic review of the
literature. Int J Psychiatry Med. 2002;32:235–47.
23. Björck C, Clinton D, Sohlberg S, Hällström T, Norring C. Interpersonal profiles
in eating disorder: ratings of SASB self-image. Psychol Psychother Theory
Res Pract. 2010;76:337–49.
24. Jones JM, Lawson ML, Daneman D, Olmsted MP, Rodin G. Eating disorders
in adolescent females with and without type 1 diabetes: cross sectional
study. BMJ. 2000;320:1563–66.
25. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al.
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in
diabetes mellitus. Ann Intern Med. 2004;141:421–31.
26. Nordwall M, Arnqvist HJ, Bojestig M, Ludvigsson J. Good glycemic control
remains crucial in prevention of late diabetic complications – the Linkoping
Diabetes Complications Study. Pediatr Diabetes. 2009;10:168–76.
27. Reynolds RM, Labad J, Strachan MWJ, Braun A, Fowkes FGR, Lee A, et al.
Elevated fasting plasma cortisol is associated with ischemic heart disease
and its risk factors in people with type 2 diabetes: the Edinburgh type 2
diabetes study. J Clinical Endocrinol Metabol. 2010;95:1602–08.
28. Reynolds RM, Strachan MWJ, Labad J, Lee AJ, Frier BM, Fowkes FG, et al.
Morning cortisol levels and cognitive abilities in people with type 2
diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2010;33:714–20.
29. Bergdahl J. Psychosomatics. Affect based investigation and treatment of
patients with psychosomatic problems [In Swedish]. Svensk Rehabilitering.
1999;1:25–7.
30. Bergdahl J, Larsson A, Nilsson LG, Ahlstrom KR, Nyberg L. Treatment of
chronic stress in employees: subjective, cognitive and neural correlates.
Scand J Psychol. 2005;46:395–402.
31. Monsen J, Monsen K. Affects and affect consciousness: a psychotherapy
model integrating Silvan Tomkins’s affect- and script theory within the
framework of self psychology. In: Goldberg A, editor. Progress in self
Melin et al. Trials  (2016) 17:221 Page 10 of 11
psychology: pluralism in self psychology. Hillsdale: Analytic Press; 1999.
p. 287–306.
32. Melin EO, Thulesius HO, Persson BA. Affect school for chronic benign pain
patients showed improved alexithymia assessments with TAS-20.
Biopsychosoc. 2010;4:1–10.
33. Mehling WE, Wrubel J, Daubenmier J, Price CJ, Kerr CE, Silow T, et al.
Body Awareness: a phenomenological inquiry into the common ground of
mind-body therapies. Philos Ethics Humanit Med. 2011;6:1–6.
34. Gyllensten AL, Ekdahl C, Hansson L. Long-term effectiveness of basic body
awareness therapy in psychiatric outpatient care: a randomized controlled
study. Adv Physiotherapy. 2009;11:2–12.
35. Malmgren-Olsson E-B, Armelius B-A, Armelius K. A comparative outcome
study of body awareness therapy, feldenkrais, and conventional
physiotherapy for patients with nonspecific musculoskeletal disorders:
changes in psychological symptoms, pain, and self-image. Physiotherapy
Theory Practice. 2001;17:77–95.
36. Roxendal G. Body awareness therapy and the body awareness scale,
treatment and evaluation in psychiatric physiotherapy, Doctoral thesis. PhD.
Sweden: University of Gothenburg; 1985.
37. Melin E. Psychosomatic aspects on diabetes and chronic pain, alexithymia,
depression and salivary cortisol: the affect school and script analysis
therapy, Doctoral thesis. PhD. Sweden: Lund University; 2014.
38. Zigmond AS, Snaith RP. The hospital anxiety and depression scale.
Acta Psychiatr Scand. 1983;67:361–70.
39. Zöger S, Svedlund J, Holgers K-M. The Hospital Anxiety and Depression
Scale (HAD) as a screening instrument in tinnitus evaluation. Int J
Audiology. 2004;43:458–64.
40. Simonsson-Sarnecki M, Lundh LG, Torestad B, Bagby RM, Taylor GJ,
Parker JD. A Swedish translation of the 20-item Toronto Alexithymia Scale:
cross-validation of the factor structure. Scand J Psychol. 2000;41:25–30.
41. Bagby RM, Parker JD, Taylor GJ. The twenty-item Toronto Alexithymia
Scale – I. Item selection and cross-validation of the factor structure.
J Psychosom Res. 1994;38:23–32.
42. Bagby RM, Taylor GJ, Parker JD. The twenty-item Toronto Alexithymia
Scale – II. Convergent, discriminant, and concurrent validity. J Psychosom
Res. 1994;38:33–40.
43. Halvorsen MS, Monsen JT. Self-image as a moderator of change in
psychotherapy. Psychotherapy Res. 2007;17:205–17.
44. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, et al.
IFCC reference system for measurement of hemoglobin A1c in human
blood and the national standardization schemes in the United States, Japan,
and Sweden: a method-comparison study. Clin Chem. 2004;50:166–74.
45. Lavalard E, Szymezak J, Leroy N, Gillery P. Evaluation of Variant II analyzer
equipped with the new 270-2101 NU kit (Bio-Rad) for HbA 1c assay.
Ann Biol Clin. 2009;67:55–65.
46. Yaneva M, Kirilov G, Zacharieva S. Midnight salivary cortisol, measured by
highly sensitive electrochemiluminescence immunoassay, for the diagnosis
of Cushing’s syndrome. Cent Eur J Med. 2009;4:59–64.
47. Vogeser M, Durner J, Seliger E, Auernhammer C. Measurement of late-night
salivary cortisol with an automated immunoassay system. Clin Chem Lab
Med. 2006;44:1441–45.
48. Belaya ZE, Iljin AV, Melnichenko GA, Rozhinskaya LY, Dragunova NV,
Dzeranova LK, et al. Diagnostic performance of late-night salivary cortisol
measured by automated electrochemiluminescence immunoassay in obese
and overweight patients referred to exclude Cushing’s syndrome.
Endocrine. 2012;41:494–500.
49. Deutschbein T, Broecker-Preuss M, Flitsch J, Jaeger A, Althoff R, Walz MK, et
al. Salivary cortisol as a diagnostic tool for Cushing’s syndrome and adrenal
insufficiency: improved screening by an automatic immunoassay. Eur J
Endocrinol. 2012;166:613–18.
50. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al.
Blood pressure and end-stage renal disease in men. New England J Med.
1996;334:13–8.
51. Williams JMG, Barnhofer T, Crane C, Herman D, Raes F, Watkins E, et al.
Autobiographical memory specificity and emotional disorder.
Psychological Bulletin. 2007;133:122–48.
52. Cohen J. A power primer. Psychological Bulletin. 1992;112:155–59.
53. Hedeker D. A mixed-effects multinomial logistic regression model. Stat Med.
2003;22:1433–46.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Melin et al. Trials  (2016) 17:221 Page 11 of 11
